

18/ Take 1 421-24

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



X1

(43) International Publication Date
15 August 2002 (15.08.2002)

PCT

(10) International Publication Number
WO 02/062375 A1

(51) International Patent Classification⁷: **A61K 38/20, C07K 7/08, 14/54**

(21) International Application Number: **PCT/EP02/01170**

(22) International Filing Date: **5 February 2002 (05.02.2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
01102573.1 6 February 2001 (06.02.2001) EP
01103954.2 19 February 2001 (19.02.2001) EP

(71) Applicant (for all designated States except US): **MERCK PATENT GMBH (DARMSTADT); Frankfurter Strasse 250, 64293 Darmstadt (DE).**

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CARR, Francis, J. (GB/GB); Birchlea, The Holdings, Balmedie, Aberdeenshire AB23 8XU (GB). CARTER, Graham (GB/GB); Longhills Cottage, By Newmachar, Aberdeenshire AB21 7XB (GB). JONES, Tim (GB/GB); 27 Brickrow, Babraham, Cambridge CB2 4AJ (GB). WILLIAMS, Stephen (GB/GB); Drungowan Cottage, Auchleven, Insh, Aberdeeshire AB52 6QD (GB).**

(74) Common Representative: **MERCK PATENT GMBH; Frankfurter Strasse 250, 64293 Darmstadt (DE).**

(81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CZ, CA, CH, CN, CX, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**

(84) Designated States (regional): **ARIPO patent (GH, GM, KH, LS, MW, MZ, SD, SL, SZ, TZ, UG, YM, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, HR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BH, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**

Published:

with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/062375 A1

(54) Title: **MODIFIED INTERLEUKIN-1 RECEPTOR ANTAGONIST (IL-1RA) WITH REDUCED IMMUNOGENICITY**

(57) Abstract: The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of interleukin-1 receptor antagonist (IL-1RA) to result in IL-1RA proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used *in vivo*.

MODIFIED INTERLEUKIN-1 RECEPTOR ANTAGONIST (IL-1RA) WITH REDUCED IMMUNOGENICITY

FIELD OF THE INVENTION

5 The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of human interleukin-1 receptor antagonist (IL-1RA) to result in IL-1RA
10 protein variants that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used *in vivo*. The invention relates furthermore to T-cell epitope peptides derived from said non-modified protein by means of which it is possible to create modified IL-1RA variants with reduced immunogenicity.

15 BACKGROUND OF THE INVENTION

There are many instances whereby the efficacy of a therapeutic protein is limited by an unwanted immune reaction to the therapeutic protein. Several mouse monoclonal antibodies have shown promise as therapies in a number of human disease settings but in certain cases have failed due to the induction of significant degrees of a human anti-murine antibody (HAMA) response [Schroff, R. W. et al (1985) *Cancer Res.* 45: 879-885; Shawler, D.L. et al (1985) *J. Immunol.* 135: 1530-1535]. For monoclonal antibodies, a number of techniques have been developed in attempt to reduce the HAMA response [WO 89/09622; EP 0239400; EP 0438310; WO 91/06667]. These recombinant DNA approaches have generally reduced the mouse genetic information in the final antibody construct whilst increasing the human genetic information in the final construct.

25 Notwithstanding, the resultant "humanized" antibodies have, in several cases, still elicited an immune response in patients [Issacs J.D. (1990) *Sem. Immunol.* 2: 449, 456; Rebello, P.R. et al (1999) *Transplantation* 68: 1417-1420].

30 Antibodies are not the only class of polypeptide molecule administered as a therapeutic agent against which an immune response may be mounted. Even proteins of human origin and with the same amino acid sequences as occur within humans can still induce an immune response in humans. Notable examples include the therapeutic use of granulocyte-macrophage colony stimulating factor [Wadhwa, M. et al (1999) *Clin.*

Cancer Res. 5: 1353-1361] and interferon alpha 2 [Russo, D. et al (1996) *Bri. J. Haem.* 94: 300-305; Stein, R. et al (1988) *New Engl. J. Med.* 318: 1409-1413] amongst others.

A principal factor in the induction of an immune response is the presence within the
5 protein of peptides that can stimulate the activity of T-cell via presentation on MHC class II molecules, so-called "T-cell epitopes. Such potential T-cell epitopes are commonly defined as any amino acid residue sequence with the ability to bind to MHC Class II molecules. Such T-cell epitopes can be measured to establish MHC binding. Implicitly, a "T-cell epitope" means an epitope which when bound to MHC molecules can be
10 recognized by a T-cell receptor (TCR), and which can, at least in principle, cause the activation of these T-cells by engaging a TCR to promote a T-cell response. It is, however, usually understood that certain peptides which are found to bind to MHC Class II molecules may be retained in a protein sequence because such peptides are recognized as "self" within the organism into which the final protein is administered.

15 It is known, that certain of these T-cell epitope peptides can be released during the degradation of peptides, polypeptides or proteins within cells and subsequently be presented by molecules of the major histocompatibility complex (MHC) in order to trigger the activation of T-cells. For peptides presented by MHC Class II, such activation
20 of T-cells can then give rise, for example, to an antibody response by direct stimulation of B-cells to produce such antibodies.

MHC Class II molecules are a group of highly polymorphic proteins which play a central role in helper T-cell selection and activation. The human leukocyte antigen group DR
25 (HLA-DR) are the predominant isotype of this group of proteins and are the major focus of the present invention. However, isotypes HLA-DQ and HLA-DP perform similar functions, hence the resent invention is equally applicable to these. The MHC class II DR molecule is made of an alpha and a beta chain which insert at their C-termini through the cell membrane. Each hetero-dimer possesses a ligand binding domain which binds to
30 peptides varying between 9 and 20 amino acids in length, although the binding groove can accommodate a maximum of 11 amino acids. The ligand binding domain is comprised of amino acids 1 to 85 of the alpha chain, and amino acids 1 to 94 of the beta chain. DQ molecules have recently been shown to have an homologous structure and the DP family proteins are also expected to be very similar. In humans approximately 70

different allotypes of the DR isotype are known, for DQ there are 30 different allotypes and for DP 47 different allotypes are known. Each individual bears two to four DR alleles, two DQ and two DP alleles. The structure of a number of DR molecules has been solved and such structures point to an open-ended peptide binding groove with a number 5 of hydrophobic pockets which engage hydrophobic residues (pocket residues) of the peptide [Brown et al *Nature* (1993) 364: 33; Stern et al (1994) *Nature* 368: 215]. Polymorphism identifying the different allotypes of class II molecule contributes to a wide diversity of different binding surfaces for peptides within the peptide binding groove and at the population level ensures maximal flexibility with regard to the ability to 10 recognize foreign proteins and mount an immune response to pathogenic organisms.

There is a considerable amount of polymorphism within the ligand binding domain with distinct "families" within different geographical populations and ethnic groups. This polymorphism affects the binding characteristics of the peptide binding domain, thus different "families" of DR molecules will have specificities for peptides with different 15 sequence properties, although there may be some overlap. This specificity determines recognition of Th-cell epitopes (Class II T-cell response) which are ultimately responsible for driving the antibody response to β-cell epitopes present on the same protein from which the Th-cell epitope is derived. Thus, the immune response to a protein in an individual is heavily influenced by T-cell epitope recognition which is a function of the 20 peptide binding specificity of that individual's HLA-DR allotype. Therefore, in order to identify T-cell epitopes within a protein or peptide in the context of a global population, it is desirable to consider the binding properties of as diverse a set of HLA-DR allotypes as possible, thus covering as high a percentage of the world population as possible.

25 An immune response to a therapeutic protein such as the protein which is object of this invention, proceeds via the MHC class II peptide presentation pathway. Here exogenous proteins are engulfed and processed for presentation in association with MHC class II molecules of the DR, DQ or DP type. MHC Class II molecules are expressed by professional antigen presenting cells (APCs), such as macrophages and dendritic cells 30 amongst others. Engagement of a MHC class II peptide complex by a cognate T-cell receptor on the surface of the T-cell, together with the cross-binding of certain other co-receptors such as the CD4 molecule, can induce an activated state within the T-cell. Activation leads to the release of cytokines further activating other lymphocytes such as B cells to produce antibodies or activating T killer cells as a full cellular immune response.

The ability of a peptide to bind a given MHC class II molecule for presentation on the surface of an APC is dependent on a number of factors most notably its primary sequence. This will influence both its propensity for proteolytic cleavage and also its affinity for binding within the peptide binding cleft of the MHC class II molecule.

5 MHC class II / peptide complex on the APC surface presents a binding face to a particular T-cell receptor (TCR) able to recognize determinants provided both by exposed residues of the peptide and the MHC class II molecule.

In the art there are procedures for identifying synthetic peptides able to bind MHC class II molecules (e.g. WO98/52976 and WO00/34317). Such peptides may not function as T-cell epitopes in all situations, particularly, *in vivo* due to the processing pathways or other phenomena. T-cell epitope identification is the first step to epitope elimination. The identification and removal of potential T-cell epitopes from proteins has been previously disclosed. In the art methods have been provided to enable the detection of T-cell epitopes 15 usually by computational means scanning for recognized sequence motifs in experimentally determined T-cell epitopes or alternatively using computational techniques to predict MHC class II-binding peptides and in particular DR-binding peptides.

WO98/52976 and WO00/34317 teach computational threading approaches to identifying 20 polypeptide sequences with the potential to bind a sub-set of human MHC class II DR allotypes. In these teachings, predicted T-cell epitopes are removed by the use of judicious amino acid substitution within the primary sequence of the therapeutic antibody or non-antibody protein of both non-human and human derivation.

25 Other techniques exploiting soluble complexes of recombinant MHC molecules in combination with synthetic peptides and able to bind to T-cell clones from peripheral blood samples from human or experimental animal subjects have been used in the art [Kern, F. et al (1998) *Nature Medicine* 4:975-978; Kwok, W.W. et al (2001) *TRENDS in Immunology* 22: 583-588] and may also be exploited in an epitope identification strategy.

30 As depicted above and as consequence thereof, it would be desirable to identify and to remove or at least to reduce T-cell epitopes from a given in principal therapeutically valuable but originally immunogenic peptide, polypeptide or protein.

One of these therapeutically valuable molecules is "interleukin-1 receptor antagonist (IL-1RA)". The protein can be produced by recombinant technologies using a number of different host cell types. The amino acid sequence of interleukin-1 receptor antagonist (IL-1RA) (depicted as one-letter code) is as follows:

5 RPSGRKSSKMQAFRIWDVNQKTFYLRNNQLVAGYLQGPVNLEEKIDVVPIEPHALFLGIHGGKMCLSCVK
SGDETRLQLEAVNITDLSENRKQDKRFAFIRSDSGPTTSFESAACPGWFLCTAMEADQPVSLSLTNMPDEGVM
VTKFYFQ EDE

Others have provided IL-1Ra molecules [e.g. US 5,075,222], but none have recognized the importance of T-cell epitopes to the immunogenic properties of the protein nor have 10 been conceived to directly influence said properties in a specific and controlled way according to the scheme of the present invention.

However, there is a continued need for interleukin-1 receptor antagonist (IL-1RA) analogues with enhanced properties. Desired enhancements include alternative schemes 15 and modalities for the expression and purification of the said therapeutic, but also and especially, improvements in the biological properties of the protein. There is a particular need for enhancement of the *in vivo* characteristics when administered to the human subject. In this regard, it is highly desired to provide interleukin-1 receptor antagonist (IL-1RA) with reduced or absent potential to induce an immune response in the human 20 subject.

SUMMARY AND DESCRIPTION OF THE INVENTION

The present invention provides for modified forms of "interleukin-1 receptor antagonist (IL-1RA)", in which the immune characteristic is modified by means of reduced or 25 removed numbers of potential T-cell epitopes. The invention discloses sequences identified within the IL-1Ra primary sequence that are potential T-cell epitopes by virtue of MHC class II binding potential. This disclosure specifically pertains a human IL-1Ra protein being of 152 amino acid residues [Eisenburg, S.P. et al (1991) *Proc. Natl. Acad. Sci. U.S.A.* 88: 5232-5236].

30 The invention may be applied to any IL-1Ra species of molecule with substantially the same primary amino acid sequences as those disclosed herein and would include therefore IL-1Ra molecules derived by genetic engineering means or other processes and may not contain 152 amino acid residues.

35 IL-1Ra proteins such as identified from murine, bovine, canine and other mammalian sources have in common many of the peptide sequences of the present disclosure and

have in common many peptide sequences with substantially the same sequence as those of the disclosed listing. Such protein sequences equally therefore fall under the scope of the present invention.

The invention discloses sequences identified within the interleukin-1 receptor antagonist 5 (IL-1RA) primary sequence that are potential T-cell epitopes by virtue of MHC class II binding potential. This disclosure specifically pertains the human interleukin-1 receptor antagonist (IL-1RA) protein being the 152 amino acid residues.

The invention discloses also specific positions within the primary sequence of the molecule according to the invention which has to be altered by specific amino acid 10 substitution, addition or deletion without affecting the biological activity in principal. In cases in which the loss of immunogenicity can be achieved only by a simultaneous loss of biological activity it is possible to restore said activity by further alterations within the amino acid sequence of the protein.

The invention discloses furthermore methods to produce such modified molecules, above 15 all methods to identify said T-cell epitopes which have to be altered in order to reduce or remove immunogenetic sites.

The protein according to this invention would expect to display an increased circulation time within the human subject and would be of particular benefit in chronic or recurring disease settings such as is the case for a number of indications for interleukin-1 receptor 20 antagonist (IL-1RA). The present invention provides for modified forms of human IL-1RA proteins that are expected to display enhanced properties *in vivo*. These modified IL-1RA molecules can be used in pharmaceutical compositions.

In summary the invention relates to the following issues:

- 25 • a modified molecule having the biological activity of interleukin-1 receptor antagonist (IL-1RA) and being substantially non-immunogenic or less immunogenic than any non-modified molecule having the same biological activity when used *in vivo*;
- an accordingly specified molecule, wherein said loss of immunogenicity is achieved by removing one or more T-cell epitopes derived from the originally non-modified 30 molecule;
- an accordingly specified molecule, wherein said loss of immunogenicity is achieved by reduction in numbers of MHC allotypes able to bind peptides derived from said molecule;
- an accordingly specified molecule, wherein one T-cell epitope is removed;

- an accordingly specified molecule, wherein said originally present T-cell epitopes are MHC class II ligands or peptide sequences which show the ability to stimulate or bind T-cells via presentation on class II;
- an accordingly specified molecule, wherein said peptide sequences are selected from the group as depicted in Table 1;
- an accordingly specified molecule, wherein 1 – 9 amino acid residues, preferably one amino acid residue in any of the originally present T-cell epitopes are altered;
- an accordingly specified molecule, wherein the alteration of the amino acid residues is substitution, addition or deletion of originally present amino acid(s) residue(s) by other amino acid residue(s) at specific position(s);
- an accordingly specified molecule, wherein one or more of the amino acid residue substitutions are carried out as indicated in Table 2;
- an accordingly specified molecule, wherein (additionally) one or more of the amino acid residue substitutions are carried out as indicated in Table 3 for the reduction in the number of MHC allotypes able to bind peptides derived from said molecule;
- an accordingly specified molecule, wherein, if necessary, additionally further alteration usually by substitution, addition or deletion of specific amino acid(s) is conducted to restore biological activity of said molecule;
- a DNA sequence or molecule which codes for any of said modified molecule as specified above and below;
- a pharmaceutical composition comprising a modified molecule having the biological activity of interleukin-1 receptor antagonist (IL-1RA) as defined above and / or in the claims, optionally together with a pharmaceutically acceptable carrier, diluent or excipient;
- a method for manufacturing a modified molecule having the biological activity of interleukin-1 receptor antagonist (IL-1RA) as defined in any of the claims of the above-cited claims comprising the following steps: (i) determining the amino acid sequence of the polypeptide or part thereof; (ii) identifying one or more potential T-cell epitopes within the amino acid sequence of the protein by any method including determination of the binding of the peptides to MHC molecules using *in vitro* or *in silico* techniques or biological assays; (iii) designing new sequence variants with one or more amino acids within the identified potential T-cell epitopes modified in such a way to substantially reduce or eliminate the activity of the T-cell epitope as determined by the binding of the peptides to MHC molecules using *in vitro* or *in silico* techniques

or biological assays; (iv) constructing such sequence variants by recombinant DNA techniques and testing said variants in order to identify one or more variants with desirable properties; and (v) optionally repeating steps (ii) – (iv);

- a 5 accordingly specified method, wherein step (iii) is carried out by substitution, addition or deletion of 1 – 9 amino acid residues in any of the originally present T-cell epitopes;
- an accordingly specified method, wherein the alteration is made with reference to a homologous protein sequence and / or *in silico* modeling techniques;
- an accordingly specified method, wherein step (ii) of above is carried out by the following steps: (a) selecting a region of the peptide having a known amino acid residue sequence; (b) sequentially sampling overlapping amino acid residue segments of predetermined uniform size and constituted by at least three amino acid residues from the selected region; (c) calculating MHC Class II molecule binding score for each said sampled segment by summing assigned values for each hydrophobic amino acid residue side chain present in said sampled amino acid residue segment; and (d) identifying at least one of said segments suitable for modification, based on the calculated MHC Class II molecule binding score for that segment, to change overall MHC Class II binding score for the peptide without substantially reducing therapeutic utility of the peptide; step (c) is preferably carried out by using a Böhm scoring function modified to include 12-6 van der Waal's ligand-protein energy repulsive term and ligand conformational energy term by (1) providing a first data base of MHC Class II molecule models; (2) providing a second data base of allowed peptide backbones for said MHC Class II molecule models; (3) selecting a model from said first data base; (4) selecting an allowed peptide backbone from said second data base; (5) identifying amino acid residue side chains present in each sampled segment; (6) determining the binding affinity value for all side chains present in each sampled segment; and repeating steps (1) through (5) for each said model and each said backbone;
- a 13mer T-cell epitope peptide having a potential MHC class II binding activity and created from immunogenetically non-modified interleukin-1 receptor antagonist (IL-1RA), selected from the group as depicted in Table 1 and its use for the manufacture of interleukin-1 receptor antagonist (IL-1RA) having substantially no or less immunogenicity than any non-modified molecule with the same biological activity when used *in vivo*;

- a peptide sequence consisting of at least 9 consecutive amino acid residues of a 13mer T-cell epitope peptide as specified above and its use for the manufacture of interleukin-1 receptor antagonist (IL-1RA) having substantially no or less immunogenicity than any non-modified molecule with the same biological activity
- 5 when used in vivo;

The term "T-cell epitope" means according to the understanding of this invention an amino acid sequence which is able to bind MCH II, able to stimulate T-cells and / or also to bind (without necessarily measurably activating) T-cells in complex with MHC II.

- 10 The term "peptide" as used herein and in the appended claims, is a compound that includes two or more amino acids. The amino acids are linked together by a peptide bond (defined herein below). There are 20 different naturally occurring amino acids involved in the biological production of peptides, and any number of them may be linked in any order to form a peptide chain or ring. The naturally occurring amino acids employed in
- 15 the biological production of peptides all have the L-configuration. Synthetic peptides can be prepared employing conventional synthetic methods, utilizing L-amino acids, D-amino acids, or various combinations of amino acids of the two different configurations. Some peptides contain only a few amino acid units. Short peptides, e.g., having less than ten amino acid units, are sometimes referred to as "oligopeptides". Other peptides contain a
- 20 large number of amino acid residues, e.g. up to 100 or more, and are referred to as "polypeptides". By convention, a "polypeptide" may be considered as any peptide chain containing three or more amino acids, whereas a "oligopeptide" is usually considered as a particular type of "short" polypeptide. Thus, as used herein, it is understood that any reference to a "polypeptide" also includes an oligopeptide. Further, any reference to a
- 25 "peptide" includes polypeptides, oligopeptides, and proteins. Each different arrangement of amino acids forms different polypeptides or proteins. The number of polypeptides—and hence the number of different proteins—that can be formed is practically unlimited.

"Alpha carbon ($C\alpha$)" is the carbon atom of the carbon-hydrogen (CH) component that is in the peptide chain. A "side chain" is a pendant group to $C\alpha$ that can comprise a simple or complex group or moiety, having physical dimensions that can vary significantly compared to the dimensions of the peptide.

The invention may be applied to any interleukin-1 receptor antagonist (IL-1RA) species of molecule with substantially the same primary amino acid sequences as those disclosed herein and would include therefore interleukin-1 receptor antagonist (IL-1RA) molecules

derived by genetic engineering means or other processes and may not contain either 152 amino acid residues.

interleukin-1 receptor antagonist (IL-1RA) proteins such as identified from other mammalian sources have in common many of the peptide sequences of the present disclosure and have in common many peptide sequences with substantially the same sequence as those of the disclosed listing. Such protein sequences equally therefore fall under the scope of the present invention.

The invention is conceived to overcome the practical reality that soluble proteins introduced into autologous organisms can trigger an immune response resulting in development of host antibodies that bind to the soluble protein. One example amongst others, is interferon alpha 2 to which a proportion of human patients make antibodies despite the fact that this protein is produced endogenously [Russo, D. et al (1996) *ibid*; Stein, R. et al (1988) *ibid*]. It is likely that the same situation pertains to the therapeutic use of interleukin-1 receptor antagonist (IL-1RA) and the present invention seeks to address this by providing interleukin-1 receptor antagonist (IL-1RA) proteins with altered propensity to elicit an immune response on administration to the human host.

The general method of the present invention leading to the modified interleukin-1 receptor antagonist (IL-1RA) comprises the following steps:

- (a) determining the amino acid sequence of the polypeptide or part thereof;
- (b) identifying one or more potential T-cell epitopes within the amino acid sequence of the protein by any method including determination of the binding of the peptides to MHC molecules using *in vitro* or *in silico* techniques or biological assays;
- (c) designing new sequence variants with one or more amino acids within the identified potential T-cell epitopes modified in such a way to substantially reduce or eliminate the activity of the T-cell epitope as determined by the binding of the peptides to MHC molecules using *in vitro* or *in silico* techniques or biological assays. Such sequence variants are created in such a way to avoid creation of new potential T-cell epitopes by the sequence variations unless such new potential T-cell epitopes are, in turn, modified in such a way to substantially reduce or eliminate the activity of the T-cell epitope; and
- (d) constructing such sequence variants by recombinant DNA techniques and testing said variants in order to identify one or more variants with desirable properties according to well known recombinant techniques.

The identification of potential T-cell epitopes according to step (b) can be carried out according to methods described previously in the prior art. Suitable methods are disclosed in WO 98/59244; WO 98/52976; WO 00/34317 and may preferably be used to identify binding propensity of interleukin-1 receptor antagonist (IL-1RA)-derived peptides to an MHC class II molecule.

Another very efficacious method for identifying T-cell epitopes by calculation is described in the EXAMPLE which is a preferred embodiment according to this invention. In practice a number of variant interleukin-1 receptor antagonist (IL-1RA) proteins will 10 be produced and tested for the desired immune and functional characteristic. The variant proteins will most preferably be produced by recombinant DNA techniques although other procedures including chemical synthesis of interleukin-1 receptor antagonist (IL-1RA) fragments may be contemplated.

15 The results of an analysis according to step (b) of the above scheme and pertaining to the human interleukin-1 receptor antagonist (IL-1RA) protein sequence of 152 amino acid residues is presented in Table 1.

Table 1: Peptide sequences in human interleukin-1 receptor antagonist (IL-1RA) with potential human MHC class II binding activity.

20	RKSSKMQAFRIWD,	SKMQAFRIWDVNQ,	QAFRIWDVNQKTF,
	FRIWDVNQKTFYL,	RIWDVNQKTFYLR,	IWDVNQKTFYLRN,
	WDVNQKTFYLRNN,	KTFYLRNNQLVAG,	TFYLRNNQLVAGY,
	FYLRNNQLVAGYL,	LRNNQLVAGYLQG,	RNNQLVAGYLQGP,
	NQLVAGYLQGPNV,	QLVAGYLQGPNVN,	LVAGYLQGPNVNL,
25	AGYLQGPVNLEE,	GYLQGPVNLEEK,	PNVNLEEKIDVVP,
	VNLEEKIDVVPIE,	EKIDVVPIEPEHAL,	IDVVPIEPEHALFL,
	DVVPIEPEHALFLG,	VPIEPEHALFLGIH,	HALFLGIHGGKMC,
	ALFLGIHGGKMCL,	LFLGIHGGKMCLS,	LGIHGGKMCLSCV,
	GKMCLSCVKSGDE,	MCLSCVKSGDETR,	SCVKSGDETRLQL,
30	ETRLQLEAVNITD,	TRLQLEAVNITDL,	LQLEAVNITDLSE,
	EAVNITDLSENRK,	VNITDLSENRKQD,	TDLSENRKQDKRF,
	ENRKQDKRFAFIR,	KRFAFIRSDSGPT,	FAFIRSDSGPTTS,
	AFIRSDSGPTTSF,	TSFESAACPGWFL,	SFESAACPGWFLC,
	PGWFLCTAMEADQ,	WFLCTAMEADQPV,	TAMEADQPVSLTN,
35	QPVSLTNMPDEGV,	VSLTNMPDEGVMV,	TNMPDEGVMVTKF,
	PDEGVMVTKFYFQ,	EGVMVTKFYFQED,	GVMVTKFYFQEDE

Peptides are 13mers, amino acids are identified using single letter code.

The results of a design and constructs according to step (c) and (d) of the above scheme and pertaining to the modified molecule of this invention is presented in Tables 2 and 3.

5

Table 2: Substitutions leading to the elimination of potential T-cell epitopes of human interleukin-1 receptor antagonist (IL-1RA) (WT = wild type).

Residue #	WT Residue	Substitution												
10	M	A	C	D	E	G	H	K	N	P	Q	R	S	T
13	F	A	C	D	E	G	H	K	N	P	Q	R	S	T
15	I	A	C	D	E	G	H	K	N	P	Q	R	S	T
16	W	A	C	D	E	G	H	K	N	P	Q	R	S	T
18	V	A	C	D	E	G	H	K	N	P	Q	R	S	T
23	F	A	C	D	E	G	H	K	N	P	Q	R	S	T
24	Y	A	C	D	E	G	H	K	N	P	Q	R	S	T
25	L	A	C	D	E	G	H	K	N	P	Q	R	S	T
30	L	A	C	D	E	G	H	K	N	P	Q	R	S	T
31	V	A	C	D	E	G	H	K	N	P	Q	R	S	T
34	Y	A	C	D	E	G	H	K	N	P	Q	R	S	T
35	L	A	C	D	E	G	H	K	N	P	Q	R	S	T
40	V	A	C	D	E	G	H	K	N	P	Q	R	S	T
42	L	A	C	D	E	G	H	K	N	P	Q	R	S	T
46	I	A	C	D	E	G	H	K	N	P	Q	R	S	T
48	V	A	C	D	E	G	H	K	N	P	Q	R	S	T
49	V	A	C	D	E	G	H	K	N	P	Q	R	S	T
51	I	A	C	D	E	G	H	K	N	P	Q	R	S	T
56	L	A	C	D	E	G	H	K	N	P	Q	R	S	T
57	F	A	C	D	E	G	H	K	N	P	Q	R	S	T
58	L	A	C	D	E	G	H	K	N	P	Q	R	S	T
60	I	A	C	D	E	G	H	K	N	P	Q	R	S	T
65	M	A	C	D	E	G	H	K	N	P	Q	R	S	T
67	L	A	C	D	E	G	H	K	N	P	Q	R	S	T
70	V	A	C	D	E	G	H	K	N	P	Q	R	S	T
78	L	A	C	D	E	G	H	K	N	P	Q	R	S	T
80	L	A	C	D	E	G	H	K	N	P	Q	R	S	T
83	V	A	C	D	E	G	H	K	N	P	Q	R	S	T
85	I	A	C	D	E	G	H	K	N	P	Q	R	S	T
88	L	A	C	D	E	G	H	K	N	P	Q	R	S	T
98	F	A	C	D	E	G	H	K	N	P	Q	R	S	T
100	F	A	C	D	E	G	H	K	N	P	Q	R	S	T
101	I	A	C	D	E	G	H	K	N	P	Q	R	S	T
119	W	A	C	D	E	G	H	K	N	P	Q	R	S	T
120	F	A	C	D	E	G	H	K	N	P	Q	R	S	T
121	L	A	C	D	E	G	H	K	N	P	Q	R	S	T
125	M	A	C	D	E	G	H	K	N	P	Q	R	S	T
131	V	A	C	D	E	G	H	K	N	P	Q	R	S	T
133	L	A	C	D	E	G	H	K	N	P	Q	R	S	T
136	M	A	C	D	E	G	H	K	N	P	Q	R	S	T
141	V	A	C	D	E	G	H	K	N	P	Q	R	S	T
142	M	A	C	D	E	G	H	K	N	P	Q	R	S	T

Table 3: Additional substitutions leading to the removal of a potential T-cell epitope for 1 or more MHC allotypes.

Residue #	WT Residue	Substitution						
13	F	W	Y					
15	I	F	W	Y				
18	V	F	I	L	M	W	Y	
19	N	A	C	G	P	T		
20	Q	A	C	G	H	P		
21	K	P	T					
22	T	A	C	G	P			
23	F	I						
25	L	F	I	M	V	W	Y	
26	R	A	C	G	P			
27	N	A	C	G	P	T		
28	N	A	C	G	H	P	T	
29	Q	A	C	G	H	P		
30	L	I	Y					
31	V	F	I	M	W	Y		
32	A	H	K	N	P	Q	S	T
33	G	D	E	H	K	N	P	Q
34	Y	M	W					
35	L	F	I	M	V	W	Y	
36	Q	A	C	G	H	P		
37	G	D	E	H	K	N	P	Q
39	N	A	C	G	P	T		
40	V	F	I	M	W	Y		
41	N	A	C	E	G	P	S	
42	L	F	I	M	V	W	Y	
43	E	A	C	G	H	P	T	
44	E	A	C	G	P			
45	K	A	C	G	P	T		
46	I	M	W	Y				
47	D	A	C	G	H	P		
48	V	I	Y					
50	P	T						
51	I	F	W	Y				
52	E	A	C	G	P			
54	H	P	T					
57	F	M	W	Y				
60	I	M	V	W	Y			
61	H	P						
62	G	P						
63	G	P						
64	K	P						
67	L	F	I	M	V	W	Y	
68	S	A	C	G	P	T		
70	V	F	I	M	W	Y		
71	K	A	C	G	H	N	P	Q
72	S	A	C	D	E	G	H	N
73	G	C	D	E	H	K	N	P
74	D	A	C	G	P			
75	E	A	C	D	G	H	K	N
77	R	A	C	G	P			
78	L	F	I	V	W	Y		
80	L	F	I	M	V	W	Y	
81	E	A	C	G	P			
84	N	A	C	G	P			
85	I	F	W	Y				
87	D	A	C	G	P			

Residue #	WT Residue							Substitution										
	L	F	I	M	V	W	Y	S	A	C	G	P	E	A	C	G	H	P
88	L	F	I	M	V	W	Y											
89	S	A	C	G	P													
90	E	A	C	G	H	P												
91	N	H	T															
92	R	A	C	G	P													
93	K	D	H	T														
94	Q	T																
95	D	A	C	G	P													
96	K	H	T															
98	F	M	W															
102	R	A	C	G	P													
103	S	H	P															
104	D	P	T															
105	S	A	C	G	P													
106	G	D	E	H	K	N	P	Q	R	S	T							
108	T	A	C	G	P													
121	L	F	I	M	V	W	Y											
122	C	H	P	T														
123	T	A	C	G	P													
124	A	C	D	E	G	H	K	N	P	Q	R	S	T					
125	M	F	I	W	Y													
126	E	A	C	D	G	H	P											
127	A	C	D	E	G	H	K	N	P	Q	R	S	T					
128	D	A	C	G	P	T												
129	Q	A	C	G	H	P	T											
130	P	H	P															
131	V	F	I	M	W	Y												
132	S	A	C	G	P													
133	L	F	I	M	V	W	Y											
134	T	P																
135	N	A	C	G	P													
136	M	I	W															
138	D	A	C	G	P													
139	E	H	N	P	Q	S	T											

The invention relates to interleukin-1 receptor antagonist (IL-1RA) analogues in which substitutions of at least one amino acid residue have been made at positions resulting in a substantial reduction in activity of or elimination of one or more potential T-cell epitopes from the protein. One or more amino acid substitutions at particular points within any of the potential MHC class II ligands identified in Table 1 may result in a interleukin-1 receptor antagonist (IL-1RA) molecule with a reduced immunogenic potential when administered as a therapeutic to the human host. Preferably, amino acid substitutions are made at appropriate points within the peptide sequence predicted to achieve substantial reduction or elimination of the activity of the T-cell epitope. In practice an appropriate point will preferably equate to an amino acid residue binding within one of the hydrophobic pockets provided within the MHC class II binding groove.

It is most preferred to alter binding within the first pocket of the cleft at the so-called P1 or P1 anchor position of the peptide. The quality of binding interaction between the P1 anchor residue of the peptide and the first pocket of the MHC class II binding groove is recognized as being a major determinant of overall binding affinity for the whole peptide.

- 5 An appropriate substitution at this position of the peptide will be for a residue less readily accommodated within the pocket, for example, substitution to a more hydrophilic residue. Amino acid residues in the peptide at positions equating to binding within other pocket regions within the MHC binding cleft are also considered and fall under the scope of the present.

10

It is understood that single amino acid substitutions within a given potential T-cell epitope are the most preferred route by which the epitope may be eliminated. Combinations of substitution within a single epitope may be contemplated and for example can be particularly appropriate where individually defined epitopes are in overlap with each 15 other. Moreover, amino acid substitutions either singly within a given epitope or in combination within a single epitope may be made at positions not equating to the "pocket residues" with respect to the MHC class II binding groove, but at any point within the peptide sequence. Substitutions may be made with reference to an homologues structure or structural method produced using *in silico* techniques known in the art and may be 20 based on known structural features of the molecule according to this invention. All such substitutions fall within the scope of the present invention.

- Amino acid substitutions other than within the peptides identified above may be contemplated particularly when made in combination with substitution(s) made within a 25 listed peptide. For example a change may be contemplated to restore structure or biological activity of the variant molecule. Such compensatory changes and changes to include deletion or addition of particular amino acid residues from the interleukin-1 receptor antagonist (IL-1RA) polypeptide resulting in a variant with desired activity and in combination with changes in any of the disclosed peptides fall under the scope of the 30 present.


In as far as this invention relates to modified interleukin-1 receptor antagonist (IL-1RA), compositions containing such modified interleukin-1 receptor antagonist (IL-1RA) proteins or fragments of modified interleukin-1 receptor antagonist (IL-1RA) proteins and

related compositions should be considered within the scope of the invention. In another aspect, the present invention relates to nucleic acids encoding modified interleukin-1 receptor antagonist (IL-1RA) entities. In a further aspect the present invention relates to methods for therapeutic treatment of humans using the modified interleukin-1 receptor antagonist (IL-1RA) proteins.

EXAMPLE

There are a number of factors that play important roles in determining the total structure of a protein or polypeptide. First, the peptide bond, i.e., that bond which joins the amino acids in the chain together, is a covalent bond. This bond is planar in structure, essentially a substituted amide. An "amide" is any of a group of organic compounds containing the grouping -CONH-.

The planar peptide bond linking C α of adjacent amino acids may be represented as depicted below:



15

Because the O=C and the C-N atoms lie in a relatively rigid plane, free rotation does not occur about these axes. Hence, a plane schematically depicted by the interrupted line is sometimes referred to as an "amide" or "peptide plane" plane wherein lie the oxygen (O), carbon (C), nitrogen (N), and hydrogen (H) atoms of the peptide backbone. At opposite corners of this amide plane are located the C α atoms. Since there is substantially no rotation about the O=C and C-N atoms in the peptide or amide plane, a polypeptide chain thus comprises a series of planar peptide linkages joining the C α atoms.

A second factor that plays an important role in defining the total structure or conformation of a polypeptide or protein is the angle of rotation of each amide plane about the common C α linkage. The terms "angle of rotation" and "torsion angle" are hereinafter regarded as equivalent terms. Assuming that the O, C, N, and H atoms remain in the amide plane (which is usually a valid assumption, although there may be some slight deviations from planarity of these atoms for some conformations), these angles of rotation define the N and R polypeptide's backbone conformation, i.e., the structure as it

exists between adjacent residues. These two angles are known as ϕ and ψ . A set of the angles ϕ_i, ψ_i , where the subscript i represents a particular residue of a polypeptide chain, thus effectively defines the polypeptide secondary structure. The conventions used in defining the ϕ, ψ angles, i.e., the reference points at which the amide planes form a zero degree angle, and the definition of which angle is ϕ , and which angle is ψ , for a given polypeptide, are defined in the literature. See, e.g., Ramachandran et al. *Adv. Prot. Chem.* 23:283-437 (1968), at pages 285-94, which pages are incorporated herein by reference. The present method can be applied to any protein, and is based in part upon the discovery that in humans the primary Pocket 1 anchor position of MHC Class II molecule binding grooves has a well designed specificity for particular amino acid side chains. The specificity of this pocket is determined by the identity of the amino acid at position 86 of the beta chain of the MHC Class II molecule. This site is located at the bottom of Pocket 1 and determines the size of the side chain that can be accommodated by this pocket. Marshall, K. W., *J. Immunol.*, 152:4946-4956 (1994). If this residue is a glycine, then all hydrophobic aliphatic and aromatic amino acids (hydrophobic aliphatics being: valine, leucine, isoleucine, methionine and aromatics being: phenylalanine, tyrosine and tryptophan) can be accommodated in the pocket, a preference being for the aromatic side chains. If this pocket residue is a valine, then the side chain of this amino acid protrudes into the pocket and restricts the size of peptide side chains that can be accommodated such that only hydrophobic aliphatic side chains can be accommodated. Therefore, in an amino acid residue sequence, wherever an amino acid with a hydrophobic aliphatic or aromatic side chain is found, there is the potential for a MHC Class II restricted T-cell epitope to be present. If the side-chain is hydrophobic aliphatic, however, it is approximately twice as likely to be associated with a T-cell epitope than an aromatic side chain (assuming an approximately even distribution of Pocket 1 types throughout the global population).

A computational method embodying the present invention profiles the likelihood of peptide regions to contain T-cell epitopes as follows:

- (1) The primary sequence of a peptide segment of predetermined length is scanned, and all hydrophobic aliphatic and aromatic side chains present are identified. (2) The hydrophobic aliphatic side chains are assigned a value greater than that for the aromatic side chains; preferably about twice the value assigned to the aromatic side chains, e.g., a value of 2 for a hydrophobic aliphatic side chain and a value of 1 for an aromatic side chain. (3) The values determined to be present are summed for each overlapping amino

acid residue segment (window) of predetermined uniform length within the peptide, and the total value for a particular segment (window) is assigned to a single amino acid residue at an intermediate position of the segment (window), preferably to a residue at about the midpoint of the sampled segment (window). This procedure is repeated for 5 each sampled overlapping amino acid residue segment (window). Thus, each amino acid residue of the peptide is assigned a value that relates to the likelihood of a T-cell epitope being present in that particular segment (window). (4) The values calculated and assigned as described in Step 3, above, can be plotted against the amino acid coordinates of the entire amino acid residue sequence being assessed. (5) All portions of the sequence which 10 have a score of a predetermined value, e.g., a value of 1, are deemed likely to contain a T-cell epitope and can be modified, if desired. This particular aspect of the present invention provides a general method by which the regions of peptides likely to contain T-cell epitopes can be described. Modifications to the peptide in these regions have the potential to modify the MHC Class II binding characteristics.

15 According to another aspect of the present invention, T-cell epitopes can be predicted with greater accuracy by the use of a more sophisticated computational method which takes into account the interactions of peptides with models of MHC Class II alleles. The computational prediction of T-cell epitopes present within a peptide according to this particular aspect contemplates the construction of models of at least 42 MHC Class II 20 alleles based upon the structures of all known MHC Class II molecules and a method for the use of these models in the computational identification of T-cell epitopes, the construction of libraries of peptide backbones for each model in order to allow for the known variability in relative peptide backbone alpha carbon ($C\alpha$) positions, the construction of libraries of amino-acid side chain conformations for each backbone dock 25 with each model for each of the 20 amino-acid alternatives at positions critical for the interaction between peptide and MHC Class II molecule, and the use of these libraries of backbones and side-chain conformations in conjunction with a scoring function to select the optimum backbone and side-chain conformation for a particular peptide docked with a particular MHC Class II molecule and the derivation of a binding score from this 30 interaction. Models of MHC Class II molecules can be derived via homology modeling from a number of similar structures found in the Brookhaven Protein Data Bank ("PDB"). These may be made by the use of semi-automatic homology modeling software (Modeller, Sali A. & Blundell TL., 1993. *J. Mol Biol* 234:779-815) which incorporates a simulated annealing function, in conjunction with the CHARMM force-field for energy

minimisation (available from Molecular Simulations Inc., San Diego, Ca.). Alternative modeling methods can be utilized as well. The present method differs significantly from other computational methods which use libraries of experimentally derived binding data of each amino-acid alternative at each position in the binding groove for a small set of

5 MHC Class II molecules (Marshall, K.W., *et al.*, *Biomed. Pept. Proteins Nucleic Acids*, 1(3):157-162) (1995) or yet other computational methods which use similar experimental binding data in order to define the binding characteristics of particular types of binding pockets within the groove, again using a relatively small subset of MHC Class II molecules, and then 'mixing and matching' pocket types from this pocket library to

10 artificially create further 'virtual' MHC Class II molecules (Sturniolo T., *et al.*, *Nat. Biotech.* 17(6): 555-561 (1999). Both prior methods suffer the major disadvantage that, due to the complexity of the assays and the need to synthesize large numbers of peptide variants, only a small number of MHC Class II molecules can be experimentally scanned. Therefore the first prior method can only make predictions for a small number of MHC

15 Class II molecules. The second prior method also makes the assumption that a pocket lined with similar amino-acids in one molecule will have the same binding characteristics when in the context of a different Class II allele and suffers further disadvantages in that only those MHC Class II molecules can be 'virtually' created which contain pockets contained within the pocket library. Using the modeling approach described herein, the

20 structure of any number and type of MHC Class II molecules can be deduced, therefore alleles can be specifically selected to be representative of the global population. In addition, the number of MHC Class II molecules scanned can be increased by making further models further than having to generate additional data via complex experimentation. The use of a backbone library allows for variation in the positions of the

25 C α atoms of the various peptides being scanned when docked with particular MHC Class II molecules. This is again in contrast to the alternative prior computational methods described above which rely on the use of simplified peptide backbones for scanning amino-acid binding in particular pockets. These simplified backbones are not likely to be representative of backbone conformations found in 'real' peptides leading to inaccuracies

30 in prediction of peptide binding. The present backbone library is created by superposing the backbones of all peptides bound to MHC Class II molecules found within the Protein Data Bank and noting the root mean square (RMS) deviation between the C α atoms of each of the eleven amino-acids located within the binding groove. While this library can be derived from a small number of suitable available mouse and human structures

(currently 13), in order to allow for the possibility of even greater variability, the RMS figure for each C"- \square position is increased by 50%. The average C α position of each amino-acid is then determined and a sphere drawn around this point whose radius equals the RMS deviation at that position plus 50%. This sphere represents all allowed C α positions.

5 Working from the C α with the least RMS deviation (that of the amino-acid in Pocket 1 as mentioned above, equivalent to Position 2 of the 11 residues in the binding groove), the sphere is three-dimensionally gridded, and each vertex within the grid is then used as a possible location for a C α of that amino-acid. The subsequent amide plane, corresponding to the peptide bond to the subsequent amino-acid is grafted onto each of

10 these C α s and the ϕ and ψ angles are rotated step-wise at set intervals in order to position the subsequent C α . If the subsequent C α falls within the 'sphere of allowed positions' for this C α than the orientation of the dipeptide is accepted, whereas if it falls outside the sphere then the dipeptide is rejected. This process is then repeated for each of the subsequent C α positions, such that the peptide grows from the Pocket 1 C α 'seed', until

15 all nine subsequent C α s have been positioned from all possible permutations of the preceding C α s. The process is then repeated once more for the single C α preceding pocket 1 to create a library of backbone C α positions located within the binding groove. The number of backbones generated is dependent upon several factors: The size of the 'spheres of allowed positions'; the fineness of the gridding of the 'primary sphere' at the

20 Pocket 1 position; the fineness of the step-wise rotation of the ϕ and ψ angles used to position subsequent C α s. Using this process, a large library of backbones can be created. The larger the backbone library, the more likely it will be that the optimum fit will be found for a particular peptide within the binding groove of an MHC Class II molecule. Inasmuch as all backbones will not be suitable for docking with all the models of MHC

25 Class II molecules due to clashes with amino-acids of the binding domains, for each allele a subset of the library is created comprising backbones which can be accommodated by that allele. The use of the backbone library, in conjunction with the models of MHC Class II molecules creates an exhaustive database consisting of allowed side chain conformations for each amino-acid in each position of the binding groove for each MHC

30 Class II molecule docked with each allowed backbone. This data set is generated using a simple steric overlap function where a MHC Class II molecule is docked with a backbone and an amino-acid side chain is grafted onto the backbone at the desired position. Each of the rotatable bonds of the side chain is rotated step-wise at set intervals and the resultant

positions of the atoms dependent upon that bond noted. The interaction of the atom with atoms of side-chains of the binding groove is noted and positions are either accepted or rejected according to the following criteria: The sum total of the overlap of all atoms so far positioned must not exceed a pre-determined value. Thus the stringency of the

5 conformational search is a function of the interval used in the step-wise rotation of the bond and the pre-determined limit for the total overlap. This latter value can be small if it is known that a particular pocket is rigid, however the stringency can be relaxed if the positions of pocket side-chains are known to be relatively flexible. Thus allowances can be made to imitate variations in flexibility within pockets of the binding groove. This

10 conformational search is then repeated for every amino-acid at every position of each backbone when docked with each of the MHC Class II molecules to create the exhaustive database of side-chain conformations. A suitable mathematical expression is used to estimate the energy of binding between models of MHC Class II molecules in conjunction with peptide ligand conformations which have to be empirically derived by scanning the

15 large database of backbone/side-chain conformations described above. Thus a protein is scanned for potential T-cell epitopes by subjecting each possible peptide of length varying between 9 and 20 amino-acids (although the length is kept constant for each scan) to the following computations: An MHC Class II molecule is selected together with a peptide backbone allowed for that molecule and the side-chains corresponding to the

20 desired peptide sequence are grafted on. Atom identity and interatomic distance data relating to a particular side-chain at a particular position on the backbone are collected for each allowed conformation of that amino-acid (obtained from the database described above). This is repeated for each side-chain along the backbone and peptide scores derived using a scoring function. The best score for that backbone is retained and the

25 process repeated for each allowed backbone for the selected model. The scores from all allowed backbones are compared and the highest score is deemed to be the peptide score for the desired peptide in that MHC Class II model. This process is then repeated for each model with every possible peptide derived from the protein being scanned, and the scores for peptides versus models are displayed.

30 In the context of the present invention, each ligand presented for the binding affinity calculation is an amino-acid segment selected from a peptide or protein as discussed above. Thus, the ligand is a selected stretch of amino acids about 9 to 20 amino acids in length derived from a peptide, polypeptide or protein of known sequence. The terms "amino acids" and "residues" are hereinafter regarded as equivalent terms. The ligand, in

the form of the consecutive amino acids of the peptide to be examined grafted onto a backbone from the backbone library, is positioned in the binding cleft of an MHC Class II molecule from the MHC Class II molecule model library via the coordinates of the C"-
5 atoms of the peptide backbone and an allowed conformation for each side-chain is selected from the database of allowed conformations. The relevant atom identities and interatomic distances are also retrieved from this database and used to calculate the peptide binding score. Ligands with a high binding affinity for the MHC Class II binding pocket are flagged as candidates for site-directed mutagenesis. Amino-acid substitutions are made in the flagged ligand (and hence in the protein of interest) which is then retested
10 using the scoring function in order to determine changes which reduce the binding affinity below a predetermined threshold value. These changes can then be incorporated into the protein of interest to remove T-cell epitopes. Binding between the peptide ligand and the binding groove of MHC Class II molecules involves non-covalent interactions including, but not limited to: hydrogen bonds, electrostatic interactions, hydrophobic (lipophilic)
15 interactions and Van der Walls interactions. These are included in the peptide scoring function as described in detail below. It should be understood that a hydrogen bond is a non-covalent bond which can be formed between polar or charged groups and consists of a hydrogen atom shared by two other atoms. The hydrogen of the hydrogen donor has a positive charge where the hydrogen acceptor has a partial negative charge. For the
20 purposes of peptide/protein interactions, hydrogen bond donors may be either nitrogens with hydrogen attached or hydrogens attached to oxygen or nitrogen. Hydrogen bond acceptor atoms may be oxygens not attached to hydrogen, nitrogens with no hydrogens attached and one or two connections, or sulphurs with only one connection. Certain atoms, such as oxygens attached to hydrogens or imine nitrogens (e.g. C=NH) may be
25 both hydrogen acceptors or donors. Hydrogen bond energies range from 3 to 7 Kcal/mol and are much stronger than Van der Waal's bonds, but weaker than covalent bonds. Hydrogen bonds are also highly directional and are at their strongest when the donor atom, hydrogen atom and acceptor atom are co-linear. Electrostatic bonds are formed between oppositely charged ion pairs and the strength of the interaction is inversely
30 proportional to the square of the distance between the atoms according to Coulomb's law. The optimal distance between ion pairs is about 2.8 Å. In protein/peptide interactions, electrostatic bonds may be formed between arginine, histidine or lysine and aspartate or glutamate. The strength of the bond will depend upon the pKa of the ionizing group and the dielectric constant of the medium although they are approximately similar in strength

to hydrogen bonds. Lipophilic interactions are favorable hydrophobic-hydrophobic contacts that occur between the protein and peptide ligand. Usually, these will occur between hydrophobic amino acid side chains of the peptide buried within the pockets of the binding groove such that they are not exposed to solvent. Exposure of the 5 hydrophobic residues to solvent is highly unfavorable since the surrounding solvent molecules are forced to hydrogen bond with each other forming cage-like clathrate structures. The resultant decrease in entropy is highly unfavorable. Lipophilic atoms may be sulphurs which are neither polar nor hydrogen acceptors and carbon atoms which are not polar. Van der Waal's bonds are non-specific forces found between atoms which are 10 3-4 Å apart. They are weaker and less specific than hydrogen and electrostatic bonds. The distribution of electronic charge around an atom changes with time and, at any instant, the charge distribution is not symmetric. This transient asymmetry in electronic charge induces a similar asymmetry in neighboring atoms. The resultant attractive forces between atoms reaches a maximum at the Van der Waal's contact distance but diminishes 15 very rapidly at about 1 Å to about 2 Å. Conversely, as atoms become separated by less than the contact distance, increasingly strong repulsive forces become dominant as the outer electron clouds of the atoms overlap. Although the attractive forces are relatively weak compared to electrostatic and hydrogen bonds (about 0.6 Kcal/mol), the repulsive forces in particular may be very important in determining whether a peptide ligand may 20 bind successfully to a protein. In one embodiment, the Böhm scoring function (SCORE1 approach) is used to estimate the binding constant. (Böhm, H.J., *J. Comput Aided Mol. Des.*, 8(3):243-256 (1994) which is hereby incorporated in its entirety). In another embodiment, the scoring function (SCORE2 approach) is used to estimate the binding affinities as an indicator of a ligand containing a T-cell epitope (Böhm, H.J., *J. Comput 25 Aided Mol. Des.*, 12(4):309-323 (1998) which is hereby incorporated in its entirety). However, the Böhm scoring functions as described in the above references are used to estimate the binding affinity of a ligand to a protein where it is already known that the ligand successfully binds to the protein and the protein/ligand complex has had its structure solved, the solved structure being present in the Protein Data Bank ("PDB"). 30 Therefore, the scoring function has been developed with the benefit of known positive binding data. In order to allow for discrimination between positive and negative binders, a repulsion term must be added to the equation. In addition, a more satisfactory estimate of binding energy is achieved by computing the lipophilic interactions in a pairwise manner rather than using the area based energy term of the above Böhm functions.

Therefore, in a preferred embodiment, the binding energy is estimated using a modified Böhm scoring function. In the modified Böhm scoring function, the binding energy between protein and ligand (ΔG_{bind}) is estimated considering the following parameters:

5 The reduction of binding energy due to the overall loss of translational and rotational entropy of the ligand (ΔG_0); contributions from ideal hydrogen bonds (ΔG_{hb}) where at least one partner is neutral; contributions from unperturbed ionic interactions (ΔG_{ionic}); lipophilic interactions between lipophilic ligand atoms and lipophilic acceptor atoms (ΔG_{lipo}); the loss of binding energy due to the freezing of internal degrees of freedom in the ligand, i.e., the freedom of rotation about each C-C bond is reduced (ΔG_{rot}); the

10 energy of the interaction between the protein and ligand (E_{vdw}). Consideration of these terms gives equation 1:

$$(\Delta G_{bind}) = (\Delta G_0) + (\Delta G_{hb} \times N_{hb}) + (\Delta G_{ionic} \times N_{ionic}) + (\Delta G_{lipo} \times N_{lipo}) + (\Delta G_{rot} + N_{rot}) + (E_{vdw}).$$

Where N is the number of qualifying interactions for a specific term and, in one embodiment, ΔG_0 , ΔG_{hb} , ΔG_{ionic} , ΔG_{lipo} and ΔG_{rot} are constants which are given the values: 5.4, -4.7, -4.7, -0.17, and 1.4, respectively.

The term N_{hb} is calculated according to equation 2:

$$N_{hb} = \sum_{\text{h-bonds}} f(\Delta R, \Delta \alpha) \times f(N_{\text{neighb}}) \times f_{\text{pos}}$$

$f(\Delta R, \Delta \alpha)$ is a penalty function which accounts for large deviations of hydrogen bonds from ideality and is calculated according to equation 3:

$$20 \quad f(\Delta R, \Delta \alpha) = f1(\Delta R) \times f2(\Delta \alpha)$$

Where: $f1(\Delta R) = 1$ if $\Delta R \leq TOL$

or $= 1 - (\Delta R - TOL)/0.4$ if $\Delta R \leq 0.4 + TOL$

or $= 0$ if $\Delta R > 0.4 + TOL$

And: $f2(\Delta \alpha) = 1$ if $\Delta \alpha < 30^\circ$

or $= 1 - (\Delta \alpha - 30)/50$ if $\Delta \alpha \leq 80^\circ$

or $= 0$ if $\Delta \alpha > 80^\circ$

TOL is the tolerated deviation in hydrogen bond length = 0.25 Å

ΔR is the deviation of the H-O/N hydrogen bond length from the ideal value = 1.9 Å

$\Delta \alpha$ is the deviation of the hydrogen bond angle $\angle_{N/O-H..O/N}$ from its idealized value of

$$30 \quad 180^\circ$$

$f(N_{\text{neighb}})$ distinguishes between concave and convex parts of a protein surface and therefore assigns greater weight to polar interactions found in pockets rather than those found at the protein surface. This function is calculated according to equation 4 below:

$$f(N_{\text{neighb}}) = (N_{\text{neighb}}/N_{\text{neighb},0})^\alpha \quad \text{where } \alpha = 0.5$$

N_{neighb} is the number of non-hydrogen protein atoms that are closer than 5 Å to any given protein atom.

$N_{\text{neighb},0}$ is a constant = 25

f_{pcc} is a function which allows for the polar contact surface area per hydrogen bond and

- 5 therefore distinguishes between strong and weak hydrogen bonds and its value is determined according to the following criteria:

$f_{\text{pcc}} = \beta$ when $A_{\text{polar}}/N_{\text{HB}} < 10 \text{ \AA}^2$

or $f_{\text{pcc}} = 1$ when $A_{\text{polar}}/N_{\text{HB}} > 10 \text{ \AA}^2$

A_{polar} is the size of the polar protein-ligand contact surface

- 10 N_{HB} is the number of hydrogen bonds

β is a constant whose value = 1.2

For the implementation of the modified Böhm scoring function, the contributions from ionic interactions, ΔG_{ionic} , are computed in a similar fashion to those from hydrogen bonds described above since the same geometry dependency is assumed.

- 15 The term N_{lip} is calculated according to equation 5 below:

$$N_{\text{lip}} = \sum_{IL} f(r_{IL})$$

$f(r_{IL})$ is calculated for all lipophilic ligand atoms, I, and all lipophilic protein atoms, L, according to the following criteria:

$f(r_{IL}) = 1$ when $r_{IL} \leq R1$ $f(r_{IL}) = (r_{IL} - R1)/(R2 - R1)$ when $R2 < r_{IL} > R1$

- 20 $f(r_{IL}) = 0$ when $r_{IL} \geq R2$

Where: $R1 = r_I^{\text{vdw}} + r_L^{\text{vdw}} + 0.5$

and $R2 = R1 + 3.0$

and r_I^{vdw} is the Van der Waal's radius of atom I

and r_L^{vdw} is the Van der Waal's radius of atom L

- 25 The term N_{rot} is the number of rotatable bonds of the amino acid side chain and is taken to be the number of acyclic $sp^3 - sp^3$ and $sp^3 - sp^2$ bonds. Rotations of terminal -CH₃ or -NH₃ are not taken into account.

The final term, E_{vdw} , is calculated according to equation 6 below:

$$E_{\text{vdw}} = \epsilon_1 \epsilon_2 ((r_1^{\text{vdw}} + r_2^{\text{vdw}})^{12}/r^{12} - (r_1^{\text{vdw}} + r_2^{\text{vdw}})^6/r^6), \text{ where:}$$

- 30 ϵ_1 and ϵ_2 are constants dependant upon atom identity

$r_1^{\text{vdw}} + r_2^{\text{vdw}}$ are the Van der Waal's atomic radii

r is the distance between a pair of atoms.

With regard to Equation 6, in one embodiment, the constants ϵ_1 and ϵ_2 are given the atom values: C: 0.245, N: 0.283, O: 0.316, S: 0.316, respectively (i.e. for atoms of Carbon,

Nitrogen, Oxygen and Sulphur, respectively). With regards to equations 5 and 6, the Van der Waal's radii are given the atom values C: 1.85, N: 1.75, O: 1.60, S: 2.00Å.

It should be understood that all predetermined values and constants given in the equations above are determined within the constraints of current understandings of protein ligand

5 interactions with particular regard to the type of computation being undertaken herein.

Therefore, it is possible that, as this scoring function is refined further, these values and constants may change hence any suitable numerical value which gives the desired results in terms of estimating the binding energy of a protein to a ligand may be used and hence fall within the scope of the present invention. As described above, the scoring function is

10 applied to data extracted from the database of side-chain conformations, atom identities, and interatomic distances. For the purposes of the present description, the number of MHC Class II molecules included in this database is 42 models plus four solved

structures. It should be apparent from the above descriptions that the modular nature of the construction of the computational method of the present invention means that new

15 models can simply be added and scanned with the peptide backbone library and side-chain conformational search function to create additional data sets which can be

processed by the peptide scoring function as described above. This allows for the

repertoire of scanned MHC Class II molecules to easily be increased, or structures and associated data to be replaced if data are available to create more accurate models of the

20 existing alleles.

The present prediction method can be calibrated against a data set comprising a large number of peptides whose affinity for various MHC Class II molecules has previously been experimentally determined. By comparison of calculated versus experimental data, a cut off value can be determined above which it is known that all experimentally

25 determined T-cell epitopes are correctly predicted. It should be understood that, although the above scoring function is relatively simple compared to some sophisticated methodologies that are available, the calculations are performed extremely rapidly. It

should also be understood that the objective is not to calculate the true binding energy *per se* for each peptide docked in the binding groove of a selected MHC Class II protein. The

30 underlying objective is to obtain comparative binding energy data as an aid to predicting the location of T-cell epitopes based on the primary structure (i.e. amino acid sequence) of a selected protein. A relatively high binding energy or a binding energy above a selected threshold value would suggest the presence of a T-cell epitope in the ligand. The ligand may then be subjected to at least one round of amino-acid substitution and the

binding energy recalculated. Due to the rapid nature of the calculations, these manipulations of the peptide sequence can be performed interactively within the program's user interface on cost-effectively available computer hardware. Major investment in computer hardware is thus not required. It would be apparent to one skilled in the art that other available software could be used for the same purposes. In particular, more sophisticated software which is capable of docking ligands into protein binding-sites may be used in conjunction with energy minimization. Examples of docking software are: DOCK (Kuntz *et al.*, *J. Mol. Biol.*, 161:269-288 (1982)), LUDI (Böhm, H.J., *J. Comput Aided Mol. Des.*, 8:623-632 (1994)) and FLEXX (Rarey M., *et al.*, *ISMB*, 3:300-308 (1995)). Examples of molecular modeling and manipulation software include: AMBER (Tripos) and CHARMM (Molecular Simulations Inc.). The use of these computational methods would severely limit the throughput of the method of this invention due to the lengths of processing time required to make the necessary calculations. However, it is feasible that such methods could be used as a 'secondary screen' to obtain more accurate calculations of binding energy for peptides which are found to be 'positive binders' via the method of the present invention. The limitation of processing time for sophisticated molecular mechanic or molecular dynamic calculations is one which is defined both by the design of the software which makes these calculations and the current technology limitations of computer hardware. It may be anticipated that, in the future, with the writing of more efficient code and the continuing increases in speed of computer processors, it may become feasible to make such calculations within a more manageable time-frame. Further information on energy functions applied to macromolecules and consideration of the various interactions that take place within a folded protein structure can be found in: Brooks, B.R., *et al.*, *J. Comput. Chem.*, 4:187-217 (1983) and further information concerning general protein-ligand interactions can be found in: Dauber-Osguthorpe et al., *Proteins* 4(1):31-47(1988), which are incorporated herein by reference in their entirety. Useful background information can also be found, for example, in Fasman, G.D., ed., *Prediction of Protein Structure and the Principles of Protein Conformation*, Plenum Press, New York, ISBN: 0-306 4313-9.

Patent Claims

1. A modified molecule having the biological activity of interleukin-1 receptor antagonist (IL-1RA) and being substantially non-immunogenic or less immunogenic than any non-modified molecule having the same biological activity when used *in vivo*.
5
2. A molecule according to claim 1, wherein said loss of immunogenicity is achieved by removing one or more T-cell epitopes derived from the originally non-modified molecule.
10
3. A molecule according to claim 1 or 2, wherein said loss of immunogenicity is achieved by reduction in numbers of MHC allotypes able to bind peptides derived from said molecule.
15
4. A molecule according to claim 2 or 3, wherein one T-cell epitope is removed.
5. A molecule according to any of the claims 2 – 4, wherein said originally present T-cell epitopes are MHC class II ligands or peptide sequences which show the ability to stimulate or bind T-cells via presentation on class II.
20
6. A molecule according to claim 5, wherein said peptide sequences are selected from the group as depicted in Table 1.
- 25 7. A molecule according to any of the claims 2 – 6, wherein 1 – 9 amino acid residues in any of the originally present T-cell epitopes are altered.
8. A molecule according to claim 7, wherein one amino acid residue is altered.
- 30 9. A molecule according to claim 7 or 8, wherein the alteration of the amino acid residues is substitution of originally present amino acid(s) residue(s) by other amino acid residue(s) at specific position(s).

10. A molecule according to claim 9, wherein one or more of the amino acid residue substitutions are carried out as indicated in Table 2.
11. A molecule according to claim 10, wherein additionally one or more of the amino acid residue substitutions are carried out as indicated in Table 3 for the reduction in the number of MHC allotypes able to bind peptides derived from said molecule.
5
12. A molecule according to claim 9, wherein one or more amino acid substitutions are carried as indicated in Table 3.
10
13. A molecule according to claim 7 or 8, wherein the alteration of the amino acid residues is deletion of originally present amino acid(s) residue(s) at specific position(s).
- 15 14. A molecule according to claim 7 or 8, wherein the alteration of the amino acid residues is addition of amino acid(s) at specific position(s) to those originally present.
15
15. A molecule according to any of the claims 7 to 14, wherein additionally further alteration is conducted to restore biological activity of said molecule.
20
16. A molecule according to claim 15, wherein the additional further alteration is substitution, addition or deletion of specific amino acid(s).
- 25 17. A modified molecule according to any of the claims 7 – 16, wherein the amino acid alteration is made with reference to an homologous protein sequence.
18. A modified molecule according to any of the claims 7 – 16, wherein the amino acid alteration is made with reference to *in silico* modeling techniques.
30
19. A DNA sequence coding for a modified interleukin-1 receptor antagonist (IL-1RA) of any of the claims 1 – 18.

20. A pharmaceutical composition comprising a modified molecule having the biological activity of interleukin-1 receptor antagonist (IL-1RA) as defined in any of the above-cited claims, optionally together with a pharmaceutically acceptable carrier, diluent or excipient.
- 5
21. A method for manufacturing a modified molecule having the biological activity of interleukin-1 receptor antagonist (IL-1RA) as defined in any of the claims of the above-cited claims comprising the following steps:
- (i) determining the amino acid sequence of the polypeptide or part thereof;
- 10 (ii) identifying one or more potential T-cell epitopes within the amino acid sequence of the protein by any method including determination of the binding of the peptides to MHC molecules using *in vitro* or *in silico* techniques or biological assays;
- (iii) designing new sequence variants with one or more amino acids within the identified potential T-cell epitopes modified in such a way to substantially reduce or eliminate the activity of the T-cell epitope as determined by the binding of the peptides to MHC molecules using *in vitro* or *in silico* techniques or biological assays, or by binding of peptide-MHC complexes to T-cells;
- 15 (iv) constructing such sequence variants by recombinant DNA techniques and testing said variants in order to identify one or more variants with desirable properties; and
- 20 (v) optionally repeating steps (ii) – (iv).
22. A method of claim 21, wherein step (iii) is carried out by substitution, addition or deletion of 1 – 9 amino acid residues in any of the originally present T-cell epitopes.
- 25
23. A method of claim 22, wherein the alteration is made with reference to a homologues protein sequence and / or *in silico* modeling techniques.
24. A method of any of the claims 21 – 23, wherein step (ii) is carried out by the following steps: (a) selecting a region of the peptide having a known amino acid residue sequence; (b) sequentially sampling overlapping amino acid residue segments of predetermined uniform size and constituted by at least three amino acid residues from the selected region; (c) calculating MHC Class II molecule binding score for each said sampled segment by summing assigned values for each
- 30

hydrophobic amino acid residue side chain present in said sampled amino acid residue segment; and (d) identifying at least one of said segments suitable for modification, based on the calculated MHC Class II molecule binding score for that segment, to change overall MHC Class II binding score for the peptide without substantially reducing therapeutic utility of the peptide.

- 5
25. A method of claim 24, wherein step (c) is carried out by using a Böhm scoring function modified to include 12-6 van der Waal's ligand-protein energy repulsive term and ligand conformational energy term by (1) providing a first data base of 10 MHC Class II molecule models; (2) providing a second data base of allowed peptide backbones for said MHC Class II molecule models; (3) selecting a model from said first data base; (4) selecting an allowed peptide backbone from said second data base; (5) identifying amino acid residue side chains present in each sampled segment; (6) determining the binding affinity value for all side chains 15 present in each sampled segment; and repeating steps (1) through (5) for each said model and each said backbone.
26. A 13mer T-cell epitope peptide having a potential MHC class II binding activity and created from immunogenically non-modified interleukin-1 receptor antagonist 20 (IL-1RA), selected from the group as depicted in Table 1.
27. A peptide sequence consisting of at least 9 consecutive amino acid residues of a 13mer T-cell epitope peptide according to claim 26.
- 25 28. Use of a 13mer T-cell epitope peptide according to claim 26 for the manufacture of interleukin-1 receptor antagonist (IL-1RA) having substantially no or less immunogenicity than any non-modified molecule with the same biological activity when used in vivo.
- 30 29. Use of a peptide sequence according to claim 27 for the manufacture of interleukin-1 receptor antagonist (IL-1RA) having substantially no or less immunogenicity than any non-modified molecule with the same biological activity when used in vivo.

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/EP 02/01170A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K38/20 C07K7/08 C07K14/54

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, EMBL, CHEM ABS Data, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 91 17184 A (UP JOHN CO) 14 November 1991 (1991-11-14) "Modified Interleukin-1 Inhibitors" page 21, line 2 -page 23, line 5; figure 3; examples 9-11 ---	6-19
X	WO 95 10298 A (SIMON CARLOS ;POLAN MARY LAKE (US)) 20 April 1995 (1995-04-20) "Method of contraception using interleukin-1 receptor antagonist" page 12, line 18 -page 14, line 15 -& DATABASE EMBL 'Online' ICIL-1ra, 28 November 1995 (1995-11-28) POLAN M. ET AL.: "Method of contraception using interleukin-1 receptor antagonist" Database accession no. AAR73642 XP002204247 the whole document ---	6-20
X	-/-	6-20

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

2 July 2002

Date of mailing of the international search report

17/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx: 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Niebuhr-Ebel, K

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 02/01170

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 09323 A (GRIFANTINI RENATA ; BOSSU PAOLA (IT); DOMPE SPA (IT); BORASCHI DIAN) 28 March 1996 (1996-03-28) "IL-1 receptor antagonists with enhanced inhibitory activity" page 5, line 12 -page 6, line 7 page 22; table 2 ---	6-20
Y	EISENBERG S P ET AL: "PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION FROM COMPLEMENTARY DNA OF A HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 343, 25 January 1990 (1990-01-25), pages 341-346, XP002911969 ISSN: 0028-0836 the whole document ---	6-29
Y	WO 00 34317 A (ADAIR FIONA SUZANNE ; CARR FRANCIS JOSEPH (GB); HAMILTON ANITA ANNE) 15 June 2000 (2000-06-15) "Modifying protein immunogenicity" page 3, line 23 -page 13, line 13 ---	6-29
Y	WO 98 52976 A (BIOVATION LTD ; CARR FRANCIS J (GB)) 26 November 1998 (1998-11-26) "Method for the production of non-immunogenic proteins" page 3, line 1 - line 28 ---	6-29
Y	ALTUVIA Y ET AL: "RANKING POTENTIAL BINDING PEPTIDES TO MHC MOLECULES BY A COMPUTATIONAL THREADING APPROACH" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 249, no. 1, 1995, pages 244-250, XP000925520 ISSN: 0022-2836 the whole document ---	6-29
Y	SALI A ET AL: "COMPARATIVE PROTEIN MODELLING BY SATISFACTION OF SPATIAL RESTRAINTS" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 234, 1993, pages 779-815, XP002948615 ISSN: 0022-2836 the whole document ---	6-29
P, X	WO 01 42304 A (AMGEN INC ; MU SHARON X (US); XIA MIN (US); CRAVEIRO ROGER (US); GI) 14 June 2001 (2001-06-14) "Interleukin-1 receptor antagonist-related molecules and uses thereof" page 23, line 22 -page 28, line 14; figure 4A; table 1 -----	6-20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 02/01170

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: 1-5, 6-29 (partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/EP 02 01170

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-5, 6-29 (partially)

Claims 1-5 refer to a "modified molecule having the biological activity of interleukin-1 receptor antagonist (IL-1RA)...". These molecules are of unspecified constitution or structure, i.e. no true technical characterization of these compounds is given. No search can be carried out on the basis of the vague definition "substantially non-immunogenic or less immunogenic", which is, in fact, a mere recitation of the result to be achieved.

Claim 6 refers to a molecule wherein putative T-cell epitopes selected from Table 1 are removed. Said Table 1 represents a set of overlapping peptide sequences derived from the IL-1RA amino acid sequence depicted on page 5 of the description. All searches have therefore been carried out on the basis of the IL-1RA sequence compiled in table 1.

Furthermore present claims 6-20 and 26-29 relate to an extremely large number of variations. In fact, the claims contain so many options that a lack of clarity and conciseness within the meaning of Article 6 PCT and a lack of disclosure within the meaning of Article 5 PCT arises.

Consequently, claims 6-20 and 26-29 have only been searched partially.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/01170

Patent document cited in search report	Publication date		Patent family member(s)		Publication date
WO 9117184	A 14-11-1991	AU WO	7683391 A 9117184 A1		27-11-1991 14-11-1991
WO 9510298	A 20-04-1995	AU WO	8016094 A 9510298 A1		04-05-1995 20-04-1995
WO 9609323	A 28-03-1996	IT WO EP US	1269989 B 9609323 A1 0782584 A1 5922573 A		16-04-1997 28-03-1996 09-07-1997 13-07-1999
WO 0034317	A 15-06-2000	AU CN EP WO AU	1667600 A 1294596 T 1051432 A2 0034317 A2 4635699 A		26-06-2000 09-05-2001 15-11-2000 15-06-2000 24-01-2000
WO 9852976	A 26-11-1998	AU AU EP WO GB JP	736549 B2 7539398 A 0983303 A1 9852976 A1 2339430 A 2002512624 T		02-08-2001 11-12-1998 08-03-2000 26-11-1998 26-01-2000 23-04-2002
WO 0142304	A 14-06-2001	AU WO	1945001 A 0142304 A1		18-06-2001 14-06-2001